Evaxion AS (EVAX)
3.10
+0.12
(+4.03%)
USD |
NASDAQ |
Sep 02, 16:00
3.10
0.00 (0.00%)
After-Hours: 18:50
Evaxion Research and Development Expense (TTM) : 10.27M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.27M |
| March 31, 2026 | 10.14M |
| December 31, 2025 | 9.988M |
| September 30, 2025 | 9.669M |
| June 30, 2025 | 9.213M |
| March 31, 2025 | 9.769M |
| December 31, 2024 | 10.44M |
| September 30, 2024 | 10.52M |
| June 30, 2024 | 10.71M |
| March 31, 2024 | 10.89M |
| December 31, 2023 | 11.93M |
| September 30, 2023 | 13.72M |
| Date | Value |
|---|---|
| June 30, 2023 | 14.95M |
| March 31, 2023 | 16.11M |
| December 31, 2022 | 17.03M |
| September 30, 2022 | 19.06M |
| June 30, 2022 | 19.42M |
| March 31, 2022 | 20.44M |
| December 31, 2021 | 19.53M |
| September 30, 2021 | 16.25M |
| June 30, 2021 | 14.85M |
| March 31, 2021 | 12.34M |
| December 31, 2020 | 10.97M |
| September 30, 2020 | 11.07M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Autolus Therapeutics Plc | 112.42M |
| Cellectis SA | 82.95M |
| Akari Therapeutics Plc | 4.869M |
| DBV Technologies SA | 117.13M |
| argenx SE | 1.640B |